Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia (United States)

Volumn 18, Issue 12, 2016, Pages 775-784

  Ponte, Jose F ^a   Ab, Olga ^a   Lanieri, Leanne ^a   Lee, Jenny ^a   Coccia, Jennifer ^a   Bartle, Laura M ^a   Themeles, Marian ^a   Zhou, Yinghui ^a   Pinkas, Jan ^a   Ruiz Soto, Rodrigo ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; HISTONE H2AX; MIRVETUXIMAB SORAVTANSINE; PACLITAXEL; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; FOLATE RECEPTOR 1; MAYTANSINE; MONOCLONAL ANTIBODY; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IGROV-1 CELL LINE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SINGLE DRUG DOSE; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CARBOPLATIN; CELL CYCLE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MICE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PLATINUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016021211     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.11.002     Document Type: Article

References (61)

1. [1] Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
2. [2] Society AC, Cancer facts & figures. 2016, American Cancer Society.
3. [3] Lacey, J.V., Sherman, M.E., Robboy, S.L., Mutter, G.L., Prat, J., (eds.) Ovarian neoplasia, vol. 2, 2009, Churchill Livingstone Elsevier, Oxford, 601.
4. [4] Liu, J., Matulonis, U.A., New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res 20 (2014), 5150–5156.
5. [5] Luvero, D., Milani, A., Ledermann, J.A., Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6 (2014), 229–239.
6. [6] Della Pepa, C., Tonini, G., Pisano, C., Di Napoli, M., Cecere, S.C., Tambaro, R., Facchini, G., Pignata, S., Ovarian cancer standard of care: are there real alternatives?. Chin J Cancer 34 (2015), 17–27.
7. [7] Davis, A., Tinker, A.V., Friedlander, M., “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?. Gynecol Oncol 133 (2014), 624–631.
8. [8] Symeonides, S., Gourley, C., Ovarian cancer molecular stratification and tumor heterogeneity: a necessity and a challenge. Front Oncol, 5, 2015, 229.
9. [9] Jansen, G., Peters, G.J., Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer. Pteridines 26 (2015), 41–53.
10. [10] Elnakat, H., Ratnam, M., Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56 (2004), 1067–1084.
11. [11] Assaraf, Y.G., Leamon, C.P., Reddy, J.A., The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat 17 (2014), 89–95.
12. [12] Ledermann, J.A., Canevari, S., Thigpen, T., Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 26 (2015), 2034–2043.
13. [13] Kalli, K.R., Oberg, A.L., Keeney, G.L., Christianson, T.J., Low, P.S., Knutson, K.L., Hartmann, L.C., Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108 (2008), 619–626.
14. [14] Wu, M., Gunning, W., Ratnam, M., Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8 (1999), 775–782.
15. [15] Toffoli, G., Russo, A., Gallo, A., Cernigoi, C., Miotti, S., Sorio, R., Tumolo, S., Boiocchi, M., Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 79 (1998), 121–126.
16. [16] Chen, Y.L., Chang, M.C., Huang, C.Y., Chiang, Y.C., Lin, H.W., Chen, C.A., Hsieh, C.Y., Cheng, W.F., Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 6 (2012), 360–369.
17. [17] Salazar, M.D., Ratnam, M., The folate receptor: what does it promise in tissue-targeted therapeutics?. Cancer Metastasis Rev 26 (2007), 141–152.
18. [18] Spannuth, W.A., Sood, A.K., Coleman, R.L., Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10 (2010), 431–437.
19. [19] Gokhale, M., Thakur, A., Rinaldi, F., Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent. Drug Dev Ind Pharm 39 (2013), 1315–1327.
20. [20] Dosio, F., Milla, P., Cattel, L., EC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 11 (2010), 1424–1433.
21. [21] Ambrosio, A.J., Suzin, D., Palmer, E.L., Penson, R.T., Vintafolide (EC145) for the treatment of folate-receptor-alpha positive platinum-resistant ovarian cancer. Expert Rev Clin Pharmacol 7 (2014), 443–450.
22. [22] Vergote, I., Armstrong, D., Scambia, G., Teneriello, M., Sehouli, J., Schweizer, C., Weil, S.C., Bamias, A., Fujiwara, K., Ochiai, K., et al. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol 34 (2016), 2271–2278.
23. [23] Merck and endocyte announce independent DSMB recommends vintafolide PROCEED phase 3 trial be stopped for futility following interim analysis. Editor (ed)^(eds), 2014, Endocyte, Inc [City].
24. [24] Chari, R.V., Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41 (2008), 98–107.
25. [25] Lambert, J.M., Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76 (2013), 248–262.
26. [26] Chari, R.V., Miller, M.L., Widdison, W.C., Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 53 (2014), 3796–3827.
27. [27] Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, M., Oh, D.Y., Dieras, V., Guardino, E., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783–1791.
28. [28] Lutz, R.J., Targeting the folate receptor for the treatment of ovarian cancer. Transl Cancer Res 4 (2015), 118–126.
29. [29] Erickson, H.K., Widdison, W.C., Mayo, M.F., Whiteman, K., Audette, C., Wilhelm, S.D., Singh, R., Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21 (2010), 84–92.
30. [30] Oroudjev, E., Lopus, M., Wilson, L., Audette, C., Provenzano, C., Erickson, H., Kovtun, Y., Chari, R., Jordan, M.A., Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 9 (2010), 2700–2713.
31. [31] Lopus, M., Oroudjev, E., Wilson, L., Wilhelm, S., Widdison, W., Chari, R., Jordan, M.A., Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9 (2010), 2689–2699.
32. [32] Ab, O., Whiteman, K.R., Bartle, L.M., Sun, X., Singh, R., Tavares, D., LaBelle, A., Payne, G., Lutz, R.J., Pinkas, J., et al. IMGN853, a folate receptor-alpha (FRalpha)–targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors. Mol Cancer Ther 14 (2015), 1605–1613.
33. [33] Bookman, M.A., Brady, M.F., McGuire, W.P., Harper, P.G., Alberts, D.S., Friedlander, M., Colombo, N., Fowler, J.M., Argenta, P.A., De Geest, K., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27 (2009), 1419–1425.
34. [34] du Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J.C., Kuhn, W., Orfeuvre, H., Wagner, U., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24 (2006), 1127–1135.
35. [35] Banerjee, S., Kaye, S., The role of targeted therapy in ovarian cancer. Eur J Cancer 47 Suppl 3 (2011), S116–S130.
36. [36] Colombo, N., Conte, P.F., Pignata, S., Raspagliesi, F., Scambia, G., Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. Crit Rev Oncol Hematol 97 (2015), 335–348.
37. [37] Yoshida, H., Yabuno, A., Fujiwara, K., Critical appraisal of bevacizumab in the treatment of ovarian cancer. Drug Des Devel Ther 9 (2015), 2351–2358.
38. [38] Gunderson, C.C., Moore, K.M., Mirvetuximab soravtansine. Folate receptor alpha (FRa)-targeting antibody drug conjugate, treatment of epithelial ovarian cancer. Drugs Future 41 (2016), 539–545.
39. [39] Chou, T.C., Talalay, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984), 27–55.
40. [40] Nguyen, H.N., Sevin, B.U., Averette, H.E., Perras, J., Ramos, R., Donato, D., Ochiai, K., Penalver, M., Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 11 (1993), 264–275.
41. [41] Mo, J., Eggers, P.K., Chen, X., Ahamed, M.R., Becker, T., Yong Lim, L., Raston, C.L., Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy. Sci Rep, 5, 2015, 10414.
42. [42] Kondo, N., Takahashi, A., Ono, K., Ohnishi, T., DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids, 2010, 2010, 543531.
43. [43] Imreh, G., Norberg, H.V., Imreh, S., Zhivotovsky, B., Chromosomal breaks during mitotic catastrophe trigger gammaH2AX-ATM-p53-mediated apoptosis. J Cell Sci 124 (2011), 2951–2963.
44. [44] Ye, H., Karim, A.A., Loh, X.J., Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review. Mater Sci Eng C Mater Biol Appl 45 (2014), 609–619.
45. [45] Economopoulou, M., Langer, H.F., Celeste, A., Orlova, V.V., Choi, E.Y., Ma, M., Vassilopoulos, A., Callen, E., Deng, C., Bassing, C.H., et al. Histone H2AX is integral to hypoxia-driven neovascularization. Nat Med 15 (2009), 553–558.
46. [46] Wrann, S., Kaufmann, M.R., Wirthner, R., Stiehl, D.P., Wenger, R.H., HIF mediated and DNA damage independent histone H2AX phosphorylation in chronic hypoxia. Biol Chem 394 (2013), 519–528.
47. [47] Vergote, I.B., Marth, C., Coleman, R.L., Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 34 (2015), 41–52.
48. [48] Peethambaram, P.P., Hartmann, L.C., Jonker, D.J., de Jonge, M., Plummer, E.R., Martin, L., Konner, J., Marshall, J., Goss, G.D., Teslenko, V., et al. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs 33 (2015), 321–331.
49. [49] Kummar, S., Chen, H.X., Wright, J., Holbeck, S., Millin, M.D., Tomaszewski, J., Zweibel, J., Collins, J., Doroshow, J.H., Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 9 (2010), 843–856.
50. [50] Markman, M., Bookman, M.A., Second-line treatment of ovarian cancer. Oncologist 5 (2000), 26–35.
51. [51] Pisano, C., Cecere, S.C., Di Napoli, M., Cavaliere, C., Tambaro, R., Facchini, G., Scaffa, C., Losito, S., Pizzolorusso, A., Pignata, S., Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer. J Drug Deliv, 2013, 2013, 898146.
52. [52] Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 23 (2012), 1185–1189.
53. [53] Reddy, J.A., Dorton, R., Bloomfield, A., Nelson, M., Vetzel, M., Guan, J., Leamon, C.P., Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs. Clin Cancer Res 20 (2014), 2104–2114.
54. [54] Kovtun, Y.V., Audette, C.A., Ye, Y., Xie, H., Ruberti, M.F., Phinney, S.J., Leece, B.A., Chittenden, T., Blattler, W.A., Goldmacher, V.S., Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66 (2006), 3214–3221.
55. [55] Ledermann, J.A., Marth, C., Carey, M.S., Birrer, M., Bowtell, D.D., Kaye, S., McNeish, I., Oza, A., Scambia, G., Rustin, G., et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer 21 (2011), 763–770.
56. [56] Mahner, S., Woelber, L., Mueller, V., Witzel, I., Prieske, K., Grimm, D., Keller, V.A.G., Trillsch, F., Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer. Front Oncol, 5, 2015, 211.
57. [57] Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
58. [58] Arjaans, M., Schroder, C.P., Oosting, S.F., Dafni, U., Kleibeuker, J.E., de Vries, E.G., VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 7 (2016), 21247–21258.
59. [59] Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., Jaffe, R.B., Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161 (2002), 1917–1924.
60. [60] Gerber, H.P., Ferrara, N., Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 (2005), 671–680.
61. [61] Fujita, K., Sano, D., Kimura, M., Yamashita, Y., Kawakami, M., Ishiguro, Y., Nishimura, G., Matsuda, H., Tsukuda, M., Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 18 (2007), 47–51.